- Login
- Register & Subscribe
- Language: EN FR DE
Finance, Grants, Deals
Roche invests in peptide technology
Tuesday 31 August 2010
The Roche Group has announced plans to invest $25 million upfront for access to new peptide technology that locks peptides into their biologically active shape, mimicking the structures found in nature.
Location
Switzerland
See map: Google Maps
Genzyme rejects Sanofi offer
Monday 30 August 2010
Genzyme Corp has rejected an unsolicited cash takeover bid from Sanofi-Aventis which values the company at $69 per share or $18.5 billion. The rejection was communicated in a letter to the Sanofi CEO Christopher Viehbacher.
Location
United States
See map: Google Maps
New drug development company set up in the Benelux
Thursday 26 August 2010
A new company has been set up in the Benelux to discover and develop small molecule drugs for treating bone and joint diseases. It combines assets from TiGenix NV of Belgium and Therosteon BV of the Netherlands.
Location
Belgium
CRT and Bayer to investigate new approach to gynaecological diseases
Wednesday 25 August 2010
Cancer Research Technology of the UK has signed an agreement with Bayer Schering Pharma AG to evaluate new leptin antagonist peptides as potential treatments for gynaecological diseases, including cancer.
Location
United Kingdom
See map: Google Maps
Roche to pay $100 million for US diagnostics company
Monday 23 August 2010
The Roche Group has announced plans to acquire privately-owned BioImagene Inc of Sunnyvale, California for $100 million in order to bolster its position as a provider of personalised medicines. BioImagene develops digital pathology services.
Location
Switzerland
See map: Google Maps
SkyePharma sees higher 2010 sales, installs new CEO
Thursday 19 August 2010
Building on momentum in the first-half year, SkyePharma Plc said it expects to report an increase in revenue for 2010. Driving the business forward will be the new CEO, Axel Müller, who takes over the top job from Ken Cunningham on 23 August.
Location
United Kingdom
See map: Google Maps
Active Biotech reports small loss but says partnerships are vital
Wednesday 11 August 2010
Active Biotech AB, a listed Swedish drug development company focused on manipulating the immune system to treat major diseases, said its net loss for the first half of 2010 narrowed to SEK 108.1 million from SEK 118.6 million a year earlier.
Location
Sweden
Wilex completes rights issue
Wednesday 4 August 2010
Wilex AG has announced the successful completion of a rights issue which has raised €10 million in new money. The proceeds will be used to finance the ongoing clinical development of the company’s oncology portfolio.
Location
Germany
See map: Google Maps
Shire to offer €19 per share for Movetis
Tuesday 3 August 2010
Shire Plc has announced a tender offer for the recently-listed Belgian company, Movetis NV, which has a product for chronic constipation on markets in the European Union. Shire is offering €19 per share in cash for Movetis, representing a premium of 74% to Movetis’s closing price on NYSE Euronext Brussels on 2 August 2010.
Location
Ireland
Good results put MorphoSys back on acquisition trail
Wednesday 28 July 2010
The antibody business of MorphoSys AG generated a substantial increase in sales and profits for the quarter and half year ended June 2010, giving it an unusual problem of how best to deploy its large cash holdings.
Location
Germany
See map: Google Maps
Select a News Category
Recent Appointments
Colin Stewart appointed CEO at Amarin
Friday August 20 2010
Karl Keegan nominated as CFO of Pharming
Friday August 20 2010
Axel Müller becomes CEO at SkyePharma
Thursday August 19 2010
Colin Bond appointed CFO at Evotec
Thursday August 12 2010
Orexo appoints Robin Wright as finance director
Tuesday August 10 2010